Literature DB >> 17010165

Interaction of HIV-1 with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-expressing cells is influenced by gp120 envelope modifications associated with disease progression.

Alexey A Nabatov1, Thijs van Montfort, Teunis B H Geijtenbeek, Georgios Pollakis, William A Paxton.   

Abstract

Dendritic cells can enhance the replication of HIV-1 in CD4(+) lymphocytes through the interaction of the gp120 envelope protein with such molecules as dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. The variable loops of gp120 have previously been shown to modulate the interaction of HIV-1 with its principal receptor CD4 and its various coreceptors, namely CCR5 and CXCR4. Here, we utilized a panel of molecular cloned viruses to identify whether gp120 modifications can influence the virus interaction with immature dendritic cells or a cell line expressing dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (Raji-DC-SIGN). The viruses encompass the R5, R5X4 and X4 phenotypes, and are based upon V1V2 and V3 sequences from a patient with disease progression. We found that dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin enhancement of virus replication can be modulated by the V1V2 length, the overall V3 charge and N-linked glycosylation patterns; similar results were observed with immature dendritic cells. Viruses with higher V3 charges are more readily transferred to CD4(+) lymphocytes when the V1V2 region is longer and contains an additional N-linked glycosylation site, whereas transfer of viruses with lower V3 charges is greater when the V1V2 region is shorter. Viruses differing in the V1V2 and V3 regions also demonstrated differential capture by Raji-DC-SIGN cells in the presence of mannan. These results indicate that the interaction between HIV-1 and immature dendritic cells via such molecules as dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin may have a role in selecting viruses undergoing transmission and evolution during disease progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010165     DOI: 10.1111/j.1742-4658.2006.05491.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  6 in total

1.  Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans.

Authors:  Thijs van Montfort; Adri A M Thomas; Georgios Pollakis; William A Paxton
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

2.  Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes.

Authors:  Marloes A Naarding; Elly Baan; Georgios Pollakis; William A Paxton
Journal:  Retrovirology       Date:  2007-01-30       Impact factor: 4.602

3.  HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.

Authors:  Meimei Shan; Per Johan Klasse; Kaustuv Banerjee; Antu K Dey; Sai Prasad N Iyer; Robert Dionisio; Dustin Charles; Lila Campbell-Gardener; William C Olson; Rogier W Sanders; John P Moore
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

4.  Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression.

Authors:  Marie Borggren; Johanna Repits; Carlotta Kuylenstierna; Jasminka Sterjovski; Melissa J Churchill; Damian F J Purcell; Anders Karlsson; Jan Albert; Paul R Gorry; Marianne Jansson
Journal:  Retrovirology       Date:  2008-03-27       Impact factor: 4.602

Review 5.  HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting Cells.

Authors:  Charles R Rinaldo
Journal:  Scientifica (Cairo)       Date:  2013-05-07

6.  Selective transmission of some HIV-1 subtype C variants might depend on Envelope stimulating dendritic cells to secrete IL-10.

Authors:  Evelyn Ngwa Lumngwena; Bianca Abrahams; Liliwe Shuping; Claudia Cicala; James Arthos; Zenda Woodman
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.